GLP-1-mediated delivery of tesaglitazar improves obesity and glucose metabolism in male mice

[1]  B. Staels,et al.  PPAR control of metabolism and cardiovascular functions , 2021, Nature Reviews Cardiology.

[2]  A. Vidal-Puig,et al.  GTTs and ITTs in mice: simple tests, complex answers , 2021, Nature Metabolism.

[3]  F. Rigo,et al.  Targeted Delivery of Antisense Oligonucleotides Using Neurotensin Peptide. , 2020, Journal of medicinal chemistry.

[4]  J. Ahnfelt-Rønne,et al.  Semaglutide lowers body weight in rodents via distributed neural pathways. , 2020, JCI insight.

[5]  Fabian J Theis,et al.  Targeted pharmacological therapy restores β-cell function for diabetes remission , 2020, Nature Metabolism.

[6]  H. Lebovitz.  Thiazolidinediones: the Forgotten Diabetes Medications , 2019, Current Diabetes Reports.

[7]  M. Blüher,et al.  NPY1R-targeted peptide-mediated delivery of a dual PPARα/γ agonist to adipocytes enhances adipogenesis and prevents diabetes progression , 2019, Molecular metabolism.

[8]  P. Balakumar,et al.  A Contemporary Overview of PPARα/γ Dual Agonists for the Management of Diabetic Dyslipidemia , 2019, Current molecular pharmacology.

[9]  D. Belsham,et al.  Bisphenol A induces Pomc gene expression through neuroinflammatory and PPARγ nuclear receptor-mediated mechanisms in POMC-expressing hypothalamic neuronal models , 2019, Molecular and Cellular Endocrinology.

[10]  C. Ämmälä,et al.  Targeted delivery of antisense oligonucleotides to pancreatic β-cells , 2018, Science Advances.

[11]  Knut Conradsen,et al.  Integrated Brain Atlas for Unbiased Mapping of Nervous System Effects Following Liraglutide Treatment , 2018, Scientific Reports.

[12]  Heng Zhang,et al.  Hypothalamic peroxisome proliferator-activated receptor gamma regulates ghrelin production and food intake , 2018, Neuropeptides.

[13]  N. Lambert,et al.  Mini G protein probes for active G protein–coupled receptors (GPCRs) in live cells , 2018, The Journal of Biological Chemistry.

[14]  Casper Bo Jensen,et al.  Characterization of the Glucagonlike Peptide-1 Receptor in Male Mouse Brain Using a Novel Antibody and In Situ Hybridization , 2018, Endocrinology.

[15]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[16]  T. Strom,et al.  Molecular Integration of Incretin and Glucocorticoid Action Reverses Immunometabolic Dysfunction and Obesity. , 2017, Cell metabolism.

[17]  J. Eeckhoute,et al.  Distinct but complementary contributions of PPAR isotypes to energy homeostasis. , 2017, The Journal of clinical investigation.

[18]  H. Fuchs,et al.  Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease , 2016, Cell.

[19]  Oliver M. Bernhardt,et al.  Extending the Limits of Quantitative Proteome Profiling with Data-Independent Acquisition and Application to Acetaminophen-Treated Three-Dimensional Liver Microtissues* , 2015, Molecular & Cellular Proteomics.

[20]  M. Mulero,et al.  Analysis of RXR/THR and RXR/PPARG2 Heterodimerization by Bioluminescence Resonance Energy Transfer (BRET) , 2013, PloS one.

[21]  Bin Yang,et al.  Targeted estrogen delivery reverses the metabolic syndrome , 2012, Nature Medicine.

[22]  M. Karlsson,et al.  Pharmacokinetic‐Pharmacodynamic Assessment of the Interrelationships Between Tesaglitazar Exposure and Renal Function in Patients With Type 2 Diabetes Mellitus , 2012, Journal of clinical pharmacology.

[23]  L. Delbridge,et al.  Heteromerization of angiotensin receptors changes trafficking and arrestin recruitment profiles. , 2011, Cellular signalling.

[24]  J. Olefsky,et al.  Brain PPARγ Promotes Obesity and is Required for the Insulin–Sensitizing Effect of Thiazolidinediones , 2011, Nature Medicine.

[25]  S. Woods,et al.  A role for CNS PPARγ in the regulation of energy balance , 2011, Nature Medicine.

[26]  T. Lan,et al.  Internalization Dissociates β2-Adrenergic Receptors , 2011, PloS one.

[27]  D. Grobbee,et al.  Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis , 2010, The Lancet.

[28]  J. Geddes,et al.  What is a randomised controlled trial? , 2009, Epidemiologia e Psichiatria Sociale.

[29]  E. Wolf,et al.  Diabetic kidney lesions of GIPRdn transgenic mice: podocyte hypertrophy and thickening of the GBM precede glomerular hypertrophy and glomerulosclerosis. , 2009, American journal of physiology. Renal physiology.

[30]  R. Printz,et al.  Expression of peroxisome proliferator-activated receptor-gamma in key neuronal subsets regulating glucose metabolism and energy homeostasis. , 2009, Endocrinology.

[31]  R. Ratner,et al.  Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes , 2007, Diabetes & vascular disease research.

[32]  H. Bays,et al.  A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus , 2007, Diabetes & vascular disease research.

[33]  John P H Wilding,et al.  Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes , 2007, Diabetes & vascular disease research.

[34]  B. Göke,et al.  The effects of tesaglitazar as add-on treatment to metformin in patients with poorly controlled type 2 diabetes , 2007, Diabetes & vascular disease research.

[35]  D. Hum,et al.  Safety issues and prospects for future generations of PPAR modulators. , 2007, Biochimica et biophysica acta.

[36]  D. Decamp,et al.  Use of a cAMP BRET Sensor to Characterize a Novel Regulation of cAMP by the Sphingosine 1-Phosphate/G13 Pathway* , 2007, Journal of Biological Chemistry.

[37]  B. Staels,et al.  PPARα and PPARγ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome , 2006 .

[38]  R. DeFronzo,et al.  Improvement of Glycemic Control, Triglycerides, and HDL Cholesterol Levels With Muraglitazar, a Dual (α/γ) Peroxisome Proliferator–Activated Receptor Activator, in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy , 2006, Diabetes Care.

[39]  Erland Erdmann,et al.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.

[40]  J. Miyazaki,et al.  Establishment of a pancreatic beta cell line that retains glucose-inducible insulin secretion: special reference to expression of glucose transporter isoforms. , 1990, Endocrinology.

[41]  J. Huttunen,et al.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.

[42]  B. Staels,et al.  PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD , 2017, Nature Reviews Endocrinology.

[43]  A. Secher,et al.  Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain. , 2015, Endocrinology.

[44]  B. Staels,et al.  PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. , 2006, Current opinion in pharmacology.

[45]  R. DeFronzo,et al.  Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-compa , 2006, Diabetes care.

[46]  J. Rosenstock,et al.  Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial. , 2006, Current medical research and opinion.

[47]  P. Allhoff,et al.  Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle Aged Men with Dyslipidemia , 1991 .